GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the…
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity…
WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi,…
Live conference call on Friday, March 10 at 8:30 a.m. ETMIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:…
MINNEAPOLIS, March 06, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic…
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics…
Company on track to achieve target cash savings of $30 - $35 million in 2023 vs 2022; expects to report…
Figure 1 Fluoresceine angiogram data from three animals treated with NM3086 (bottom) and three that received placebo control. The picture…
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to…
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless…